Effect of highly active antiretroviral therapy on outcomes in Veterans Affairs Medical Centers

AIDS

Volumn 15, Issue 4, 2001, Pages 530-532

  Goetz, Matthew Bidwell ^{a,b,c,d,e,f,g,h}   Morreale, Anthony P ^{a,b,c,d,e,f,g,h}   Rhew, David C ^{a,b,c,d,e,f,g,h}   Berman, Stephen ^{a,b,c,d,e,f,g,h}   Ing, Michael ^{a,b,c,d,e,f,g,h}   Eldridge, Dian ^{a,b,c,d,e,f,g,h}   Justis, Janice C ^{a,b,c,d,e,f,g,h}   Lott, Ed ^{a,b,c,d,e,f,g,h}  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d Jerry L Pettis Memorial VA Medical Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG EFFICACY; HEALTH CARE COST; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

AMBULATORY CARE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALIFORNIA; DRUG COSTS; HIV INFECTIONS; HOSPITALIZATION; HOSPITALS, VETERANS; HUMANS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035831236     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200103090-00015     Document Type: Article

References (14)

1. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
2. Costs of HIV medical care in the era of highly active antiretroviral therapy
3. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital
4. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center
5. Tortiously liable billing rates for fiscal year 2000
6. Economic impact of delaying or preventing AIDS in persons with HIV
7. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study
8. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: Application to a clinical trial
9. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy
10. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs
11. Declining morbidity and mortality among patients with advance human immunodeficiency virus infection
12. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients
13. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy